We have read with great interest the description of neuropathological findings in a deceased 11-month-old child with PIGT-CDG (compound heterozygote, c.1472T>A; c.1484+2T>A), described by Dr KB Larsen et al. (1). This ultra-rare disease, a defect in glycosylphosphatidylinositol (GPI) biosynthesis, is also known under the acronym MCAHS3, multiple congenital anomalies-hypotonia-seizures syndrome-3 (OMIM 615398). Accordingly, hypotonia, markedly delayed development and epilepsy are among the core manifestations.